Significant Amelioration of Tracheal Stenosis following Lenvatinib in a Patient Who Has Anaplastic Thyroid Carcinoma with Bronchomediastinal Infiltration: A Case Report

Fukuhara, Takahiro; Donishi, Ryohei; Koyama, Satoshi; Miyake, Naritomo; Matsuda, Eriko; Fujiwara, Kazunori; Kitano, Hiroya; Takeuchi, Hiromi

doi:10.1159/000457831

Cited by 8 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also a case report from Japan showed significant amelioration of tracheal stenosis following lenvatinib in a patient who had ATC with bronchial and mediastinal infiltration. The patient had failed radiation and chemotherapy prior to receiving lenvatinib (30). A phase II trial of lenvatinib, an open label, single arm, multi-center study for the treatment of ATC was prematurely stopped due to not reaching the minimum outcome expected.…”

Section: Resultsmentioning

confidence: 99%

Clinical Trials in Management of Anaplastic Thyroid Carcinoma; Progressions and Set Backs: A Systematic Review

Salehian¹,

Liem²,

Amiri³

et al. 2019

Int J Endocrinol Metab

View full text Add to dashboard Cite

Context Anaplastic thyroid carcinoma (ATC) is associated with rapid tumor growth and extremely poor prognosis. Although ATC is found in only 2% of all thyroid carcinomas, it accounts for up to 50% of thyroid cancer mortality. Objective To understand the effect of different treatment modalities upon anaplastic thyroid cancer outcomes. Methods A systematic review of studies from 1995 to 2017 was performed employing the search terms “anaplastic thyroid” and “treatment” in PubMed. Studies comparing patients receiving any type of therapy for ATC and measuring either survival as primary outcome or the percentage of patient surviving more than 1 year as secondary outcome were included for review. We did not limit sample size or subject condition. A total of 40 articles were returned from our database search, of which 25 met the inclusion criteria. Results A review of the 25 published studies indicated that early multidisciplinary approaches using extensive radical surgery, in combination with adjuvant chemo-radiation using either docetaxel/pacitaxel or cisplatin, provided the best chance of disease control. Targeted multi-tyrosine kinases inhibitors helped to limit disease progression. Also, the finding of foci of differentiated thyroid cancer within the anaplastic tumor was associated with increased long-term survival. Conclusions ATC remains a fatal disease. Despite aggressive therapy the median survival has not significantly changed over the last 20 years. However, the percentage of patients surviving longer than 1 year continues to increase. Novel approaches incorporating multiple targeted therapy and immune therapies are critically needed.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical Trials in Management of Anaplastic Thyroid Carcinoma; Progressions and Set Backs: A Systematic Review

Salehian¹,

Liem²,

Amiri³

et al. 2019

Int J Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…In the present case, we repeatedly administered lenvatinib to the patient despite severe side effects, including PRES, because we thought that lenvatinib would prolong her survival. It was recently reported that lenvatinib treatment was effective for locally advanced ATC and led to an improved quality of life as well as prolonged survival in Japanese patients ( 2 , 23 ). As previously mentioned, most ATC patients die within 6 months of the diagnosis ( 1 - 3 ).…”

Section: Discussionmentioning

confidence: 99%

Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma

et al. 2018

View full text Add to dashboard Cite

Posterior reversible encephalopathy syndrome (PRES) is a rare reversible neurological syndrome that causes subcortical vasogenic brain edema and which is associated with the use of target-specific agents. Lenvatinib is a target-specific agent that was recently approved for inoperable thyroid cancer. We herein describe the case of a 66-year-old woman with anaplastic thyroid cancer (ATC) who was treated with lenvatinib and who subsequently developed PRES. The clinical and radiological findings improved after suspending therapy for 1 week, and there was no recurrence with intermittent lower-dose lenvatinib treatment. Lenvatinib may prolong survival in patients with ATC and can be administered intermittently, even after PRES onset.

show abstract

“…Recent anecdotal evidence and a phase II clinical study have reported the antineoplastic activity of lenvatinib in ATC (16)(17)(18)(19)(20). In the present study, we aimed to evaluate the antineoplastic activity of lenvatinib in ATC continuous cell lines and in primary ATC cell cultures both in vitro and in vivo.…”

Section: Introductionmentioning

confidence: 98%

Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo

et al. 2018

View full text Add to dashboard Cite

Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor (TKI) of VEGFR1-VEGFR3, FGFR1-FGFR4, PDGFRα, RET and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling networks involved in tumor angiogenesis. We have evaluated the antitumor activity of lenvatinib in primary anaplastic thyroid cancer (ATC) cells, in the human cell line 8305C (undifferentiated thyroid cancer) and in an ATC-cell line (AF). The AF cell line was obtained from the primary ATC cultures and was the one that grew over 50 passages. The effect of lenvatinib (1 and 100 nM; and 1, 10, 25 and 50 µM) was investigated in primary ATC, 8305C and AF cells as well as in AF cells in CD nu/nu mice. Lenvatinib significantly reduced ATC cell proliferation (P<0.01, ANOVA) and increased the percentage of apoptotic ATC cells (P<0.001, ANOVA). Furthermore, lenvatinib inhibited migration (P<0.01) and invasion (P<0.001) in ATC. In addition, lenvatinib inhibited EGFR, AKT and ERK1/2 phosphorylation and downregulated cyclin D1 in the ATC cells. Lenvatinib also significantly inhibited 8305C and AF cell proliferation, increasing apoptosis. AF cells were subcutaneously injected into CD nu/nu mice and tumor masses were observed 20 days later. Tumor growth was significantly inhibited by lenvatinib (25 mg/kg/day), as well as the expression of VEGF-A and microvessel density in the AF tumor tissues. In conclusion, the antitumor and antiangiogenic activities of lenvatinib may be promising for the treatment of anaplastic thyroid cancer, and may consist a basis for future clinical therapeutic applications.

show abstract

Significant Amelioration of Tracheal Stenosis following Lenvatinib in a Patient Who Has Anaplastic Thyroid Carcinoma with Bronchomediastinal Infiltration: A Case Report

Cited by 8 publications

References 14 publications

Clinical Trials in Management of Anaplastic Thyroid Carcinoma; Progressions and Set Backs: A Systematic Review

Clinical Trials in Management of Anaplastic Thyroid Carcinoma; Progressions and Set Backs: A Systematic Review

Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma

Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo

Contact Info

Product

Resources

About